Pharming Group N.V.
PHAR Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$11.90
KIRA · Stoqly’s AI analyst, in plain words
- Pharming Group N.V. had $376M of revenue in fiscal 2025, up 26.6% on the year before. Over five years, revenue changed +12.1% a year on average.
- Its operating margin was 6.9%, up 9.8 pts: of every 100 in sales, about 7 is left after running the business.
- Pharming Group N.V. made $2.9M of net profit in fiscal 2025. From fiscal 2019 to 2025, diluted EPS grew −36.3% a year.
- Free cash flow was $54.0M in fiscal 2025, 14.3% of revenue.
Market cap
$889M
P/E
—
Revenue
$376M
Net income
$2.9M
Free cash flow
$54.0M
Operating margin
6.9%
Pharming Group N.V. in 30 seconds · fiscal 2025
Are sales growing?
+26.6%
Yes. Sales grew 26.6% last year.
Does it make a profit?
0.8%
A little. It keeps 0.8% of every sale as profit.
Does profit turn into cash?
14.3%
Yes. 14.3% of sales ends up as free cash.
How healthy are the accounts?
6 / 8
Mixed. It passes 6 of 8 health tests.
What Pharming Group N.V. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 2, 2026
- Legal name
- Pharming Group N.V.
- CIK
- 0001828316
Pharming Group N.V. · PHAR
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $199M | $206M | $245M | $297M | $376M |
| Revenue growth | −6.3% | 3.4% | 19.3% | 21.1% | 26.6% |
| Gross margin | 89.4% | 91.5% | 89.7% | 88.1% | 87.9% |
| Operating margin | 6.8% | 8.9% | −2.2% | −2.9% | 6.9% |
| Net income | $16.0M | $13.7M | −$10.5M | −$11.8M | $2.9M |
| Net margin | 8.0% | 6.7% | −4.3% | −4.0% | 0.8% |
| Diluted EPS | $0.23 | $0.19 | −$0.16 | −$0.18 | $0.04 |
| Cash | |||||
| Cash from operations | $37.8M | $22.5M | −$17.3M | −$1.8M | $54.7M |
| Capital expenditure | $10.7M | $1.4M | $1.4M | $0.8M | $0.7M |
| Free cash flow | $27.1M | $21.1M | −$18.7M | −$2.6M | $54.0M |
| FCF margin | 13.6% | 10.3% | −7.6% | −0.9% | 14.3% |
| Share count change | 2.7% | 0.9% | 2.6% | 8.3% | −4.9% |
| Debt and strength | |||||
| Cash and short-term investments | $192M | $207M | $61.7M | $54.9M | $145M |
| Shareholders' equity | $193M | $205M | $219M | $221M | $277M |
| Current ratio | 5.3x | 4.6x | 4.1x | 3.8x | 2.6x |
| Interest coverage | 144.3x | 173.6x | −40.2x | −153.9x | 131.8x |
| Returns and quality | |||||
| Return on equity | 8.5% | 6.9% | −5.0% | −5.4% | 1.1% |
| Return on tangible equity | 14.7% | 10.6% | −7.2% | −7.4% | 2.0% |
| Piotroski F-score | 5 | 4 | 1 | 2 | 6 |
| Altman Z'' | 2.3 | 2.7 | 2.4 | 2.3 | 2.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pharming Group N.V. · PHAR
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $11.90 a share, the company is worth $889M.
Source: SEC EDGAR XBRL filings (CIK 0001828316). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.